The Mark Of McClellan? Commissioner Downplays Role In Drug Approvals
Executive Summary
FDA Commissioner McClellan's direct contribution to product reviews is limited to drawing on a network of outside experts to assist in decisions, the commissioner suggested during a May 16 Manhattan Institute-sponsored roundtable with buy-side analysts
You may also be interested in...
FDA Staffing Up For Globalization: GMPs Are One Focus, McClellan Tells DIA
FDA is ramping up its efforts to harmonize international regulatory policy by involving more senior agency management, FDA Commissioner McClellan said at the Drug Information Association annual meeting in San Antonio
FDA Staffing Up For Globalization: GMPs Are One Focus, McClellan Tells DIA
FDA is ramping up its efforts to harmonize international regulatory policy by involving more senior agency management, FDA Commissioner McClellan said at the Drug Information Association annual meeting in San Antonio
Ranexa Run-Up Shows Breadth Of Biotech Rally On Wall Street
CV Therapeutics is a quiet beneficiary of the FDA advisory committee decision regarding the risk of QT prolongation with GSK/Bayer's erectile dysfunction agent Levitra and Sanofi's benign prostatic hyperplasia treatment UroXatral